Based on these findings, we propose that CLDN1 and CLDN7 may serve as the foundation of a claudin-based gene signature for CRC that can help in the identification of patients who are susceptible to chemoresistant and recurrent tumors. This evidence concerns the gene CLDN7 and colorectal carcinoma.